Claims for Patent: 8,394,076

Summary for Patent: 8,394,076

Title:	Laser assisted therapeutic agent delivery into a targeted tissue
Abstract:	The present invention involves selectively breaking down or altering a blocking tissue by irradiating the blocking tissue with a laser irradiation. Breaking down the blocking tissue allows the delivery of therapeutic agents through the blocking tissue to a target tissue. An area of the blocking tissue is selected for treatment. The selected area is irradiated with a laser to induce an alteration or breakdown of the blocking tissue. Areas not irradiated are not affected. Once the selected area of the blocking tissue is treated, a therapeutic agent can be delivered to the selected area and passed through the altered or broken down blocking tissue to the target tissue. The blocking tissue will then undergo a healing response after a period of time. The present invention may be used to treat the retina or subretinal space of a patient\'s eye through the blocking tissue of the Retinal Pigment Epithelium (RPE).
Inventor(s):	Latina; Mark A. (North Andover, MA)
Assignee:
Application Number:	12/436,511
Patent Claims:	1. A method of delivering a therapeutic agent to a retina of a patient, the method comprising: irradiating an area of a retinal pigment epithelium of a patient's eye with laser radiation in such a way that induces a breakdown or an alteration of the area in an amount sufficient to create an open area sufficient to enable the therapeutic agent to pass therethrough, the laser radiation having a fluence between about 3 .mu.Joules/cm.sup.2 and about 2 Joules/cm.sup.2; and administering the therapeutic agent to the patient after or during the step of irradiating the area of the retinal pigment epithelium, such that the therapeutic agent passes through the open area created by the laser radiation and is thereby delivered to the retina. 2. The method of claim 1, wherein the therapeutic agent is administered intravenously or by local application/injection or iontophoresis. 3. The method of claim 1, wherein administration of the therapeutic agent is achieved by one of the group of transscleral delivery, introduction of the therapeutic agent into the subtenon's space, and introduction of the therapeutic agent through a surrounding orbital tissue. 4. The method of claim 1, wherein the therapeutic agent is activated by irradiating the therapeutic agent with laser radiation. 5. The method of claim 1, wherein the area is irradiated using one or more laser pulses or a series of pulses having a duration of between about 1 ns and about 15 .mu.s. 6. The method of claim 1, wherein the laser radiation is provided by one of a q-switched Nd:YAG laser, a Pulsed-Dye laser, and a Nd:YLF laser. 7. The method of claim 1, wherein the laser radiation is provided by a q-switched Nd:YAG laser. 8. The method of claim 1, wherein the laser radiation is provided by a continuous wave laser in which the laser energy is delivered via a scanning device. 9. The method of claim 1, wherein the laser radiation is provided by a flashlamp-pumped dye laser. 10. The method of claim 1, wherein the therapeutic agent administered has a molecular weight between about 200 and 156000 daltons. 11. The method of claim 1, further comprising administering a contrast agent. 12. A method of treating a retinal disorder in a patient, said method comprising: irradiating an area of a retinal pigment epithelium of a patient's eye with laser radiation in such a way that induces a breakdown or an alteration of the area in an amount sufficient to create an open area sufficient to enable the therapeutic agent to pass therethrough, the laser radiation having a fluence between about 3 .mu.Joules/cm.sup.2 and about 2 Joules/cm.sup.2; and administering the therapeutic agent to the patient after or during the step of irradiating the area of the retinal pigment epithelium, such that the therapeutic agent passes through the open area created by the laser radiation, thereby treating the retinal disorder. 13. The method of claim 12, wherein the retinal disorder is selected from the group consisting of macular degeneration, retinitis pigmentosa and diabetic retinopathy. 14. The method of claim 12, wherein the therapeutic agent is selected from the group consisting of pegaptanib sodium, bevacizumab, VEGF Trap, and ranibizumab. 15. A method of treatment, the method comprising: irradiating a blocking tissue area with laser radiation in such a way that induces a breakdown or an alteration of the blocking tissue area in an amount sufficient to create an open area sufficient to enable the therapeutic agent to pass therethrough, the laser radiation having a fluence of between about 1 .mu.Joules/cm.sup.2 and about 2 Joules/cm.sup.2; and administering the therapeutic agent to the target tissue through the open area created by the laser radiation after or during the step of irradiating the area of the retinal pigment epithelium. 16. The method of claim 15, further comprising administering stem cells to the block tissue area to promote the healing of the blocking tissue area. 17. The method of claim 1, wherein the step of administering the therapeutic agent to the patient occurs after the step of irradiating the area of the retinal pigment epithelium. 18. The method of claim 12, wherein the step of administering the therapeutic agent to the patient occurs after the step of irradiating the area of the retinal pigment epithelium. 19. The method of claim 15, wherein the step of administering the therapeutic agent to the target tissue occurs after the step of irradiating the blocking tissue area.

Details for Patent 8,394,076

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2028-05-14
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2028-05-14
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2028-05-14
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2028-05-14
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2028-05-14